ALPHA
Filamon ALPHA drugs represents a new class of drug targeting the dual drivers of chronic disease: inflammation and degeneration.
ALPHA drugs are designed to address the paradox of chronic diseases being a mix of over-active protein-protein interactions associated with inflammation and under-activity associated with degenerative disease processes.
KESONOTIDE™ and ALPHA-D3
Filamon is advancing KESONOTIDE™ and ALPHA-D3 as lead candidates in a novel class of drugs targeting the partnership between two proteins, EGFR and vimentin, a critical partnership in both cancer progression and chronic fibrotic diseases of the lung, kidney and liver.
The EGFR (Epidermal Growth Factor Receptor) and vimentin partnership drives a biological process called epithelial-mesenchymal transition (EMT) that provides tissues with the plasticity cancers need for their aggression and invasiveness and chronic fibrotic diseases need to create fibrosis.
KESONOTIDE and ALPHA-D3 share two critical features:
- Both drug candidates block both EGFR and vimentin, increasing their ability to shut down the EMT process.
- Both drug candidates are EGFR-degraders, directing EGFR into lysosomes where they are degraded, effectively making them largely independent of EGFR mutations.
KESONOTIDE and ALPHA-D3 are analogues with slightly different drug properties. The significance of that difference is being evaluated in the clinic.
FILAMON and KESONOTIDE™ are trademarks of Filamon Limited.